EGFR and non-small cell lung carcinoma: There was no significant difference between EGFR-positive NSCLC and wildtype EGFR NSCLC in the whole cohort in 2-year DFS (70.2% [95% CI, 65.3%-74.5%] vs 67.6% [95% CI, 62.2%-72.4%]; P = .70) or 5-year DFS (50.3% [95% CI, 44.7%-55.6%] vs 50.0% [95% CI, 44.0%-55.7%]; P = .70), whereas OS for patients with EGFR-positive NSCLC was significantly improved at 2 years (95.5% [95% CI, 92.9%-97.2%] vs 88.0% [95% CI, 83.9%-91.1%]; P = .004) and at 5 years (77.7% [95% CI, 72.4%-82.1%] vs 66.6% [95% CI, 60.5%-72.0%]; P = .004) (Figure 1A and B).